A comprehensive meta-analysis in depression and mortality, led by the Department of Psychiatry at the School of Clinical ...

A 2022 study showed that 28.3% of patients receiving ketamine had a billing diagnosis of depression. McLoughlin's group ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

Psilocybin could be the future of mental health care, with promising findings emerging from Australia's first research trial ...

Findings from a randomized and blinded clinical trial investigating repeated ketamine infusions for treating depression have ...

One man living with major depressive disorder shares how working with his psychiatrist led him to understand his ...

Nurse-led depression screening in long-term care can boost diagnosis and treatment rates for older adults, according to research presented at GAPNA 2025.

Findings from a randomized and blinded clinical trial investigating repeated ketamine infusions for treating depression have ...

Ketamine is increasingly being used as an off-label treatment for depression, but researchers have found it might not provide ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that, ...

Depression may affect a person’s likelihood of achieving optimal recovery after cancer surgery, according to retrospective ...

Researchers led by Prof. Alessandro Serretti at Kore University of Enna have identified a genetic inflammatory signature that defines specific depression subtypes and influences how patients respond ...